

# **Extracorporeal Photopheresis**

**Table of Content** 

**Purpose** 

**Description & Definitions** 

**Criteria** 

Coding

**Document History** 

References

**Special Notes** 

Keywords

Effective Date 5/2008

Next Review Date 10/2024

<u>Coverage Policy</u> Medical 237

<u>Version</u> 6

Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details \*.

### Purpose:

This policy addresses the medical necessity of Extracorporeal Photopheresis.

## **Description & Definitions:**

Extracorporeal photopheresis is a nonsurgical procedure in which the individual's blood is drawn and white blood cells are separated and exposed first to a drug called 8-methoxypsoralen (8-MOP) and then to ultraviolet A (UVA) light.

#### Criteria:

Extracorporeal photopheresis is considered medically necessary with 1 or more of the following:

- Individual has acute or chronic graft-versus-host disease when the disease is refractory to standard immunosuppressive drug treatment
- Individual requires palliative treatment of skin manifestations of cutaneous T-cell lymphoma that has not responded to other therapies
- Individual has erythrodermic variants of cutaneous T cell lymphoma (e.g. Mycosis Fungoides/Sézary Syndrome (MF/SS), etc.)
- Individual has acute cardiac allograft rejection that is refractory to standard immunosuppressive drug treatment
- Individual with solid organ transplant rejection that is refractory to standard immunosuppressive drug treatment
- Individual has had a rejection of a lung transplant and 1 or more of the following:
  - Individual is refractory to immunosuppressive drug treatment
  - Individual has a rapid decline in lung function
  - Bronchiolitis obliterans syndrome (BOS)

Photopheresis is considered **not medically necessary** for any use other than those indicated in clinical criteria, to include but not limited to:

Atopic dermatitis

Medical 237 Page 1 of 3

- Autoimmune diseases (e.g., multiple sclerosis, scleroderma, diabetes mellitus [DM] type 1, rheumatoid arthritis, systemic lupus erythematosus [SLE], psoriasis, and pemphigus)
- · Crohn's disease
- Eosinophilic fasciitis
- · Graft rejection in kidney transplant recipients
- Nephrogenic systemic fibrosis (previously known as nephrogenic fibrosing dermopathy)
- · nephrogenic peritonitis

## Coding:

Medically necessary with criteria:

| Coding                              | Description                    |
|-------------------------------------|--------------------------------|
| 36522                               | Photopheresis, extracorporeal. |
| Considered Not Medically Necessary: |                                |

Considered Not Medically Necessary:

| Coding | Description |
|--------|-------------|
|        | None        |

U.S. Food and Drug Administration (FDA) - approved only products only.

# **Document History:**

#### Revised Dates:

- 2022: October
- 2021: December
- 2019: November
- 2016: January, February
- 2015: February, March
- 2014: January, November
- 2013: April, October
- 2012: September, October

#### Reviewed Dates:

- 2023: October
- 2020: December
- 2019: December
- 2018: August
- 2017: November
- 2012: April
- 2011: April
- 2010: April
- 2009: April

#### Effective Date:

May 2008

#### **References:**

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023, Jun 27). Retrieved Sep 12, 2023, from MCG: https://careweb.careguidelines.com/ed27/index.html

Medical 237 Page 2 of 3

(2023). Retrieved Sep 12, 2023, from Department of Medical Assistance Services: https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.g=pheresis&gsc.sort=

(2023). Retrieved Sep 13, 2023, from Hayes, Inc:

https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522Extracorporeal%2520photopheresis%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522,%2

Hematopoietic Cell Transplantation (HCT). (2023, Mar 31). Retrieved Sep 12, 2023, from National Comprehensive Cancer Network: https://www.nccn.org/professionals/physician\_gls/pdf/hct.pdf

NCD: Extracorporeal Photopheresis (110.4). (2012, Apr 30). Retrieved Sep 12, 2023, from Centers for Medicare and Medicaid Services: https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=113&ncdver=3&keyword=photopheresis&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1

Photopheresis. (2022). Retrieved Sep 13, 2023, from American Society of Clinical Oncology: https://www.asco.org/search?q=photopheresis&filters=%7B%22contentTypeGroupLabel%22:%5B%7B%22key%22:%22General%20Information%22%7D,%7B%22key%22:%22Abstracts%20%26%20Presentations%22%7D,%7B%22key%22:%22News%22%7D,%7B%22key%22:

UVAR CELLEX PHOTOPHERESIS SYSTEM. (2009, Mar 20). Retrieved Sep 13, 2023, from U.S. Food and Drug Administration: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=337698

Zeiser, R. (2023, Jan 17). Treatment of chronic graft-versus-host disease. Retrieved Sep 13, 2023, from UpToDate: https://www.uptodate.com/contents/treatment-of-chronic-graft-versus-host-disease?search=extracorporeal%20photopheresis&source=search\_result&selectedTitle=1~23&usage\_type=default&display\_rank=1#

## Special Notes: \*

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving, and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

Services mean both medical and behavioral health (mental health) services and supplies unless We specifically tell You otherwise. We do not cover any services that are not listed in the Covered Services section unless required to be covered under state or federal laws and regulations. We do not cover any services that are not Medically Necessary. We sometimes give examples of specific services that are not covered but that does not mean that other similar services are covered. Some services are covered only if We authorize them. When We say You or Your We mean You and any of Your family members covered under the Plan. Call Member Services if You have questions.

## Keywords:

SHP Extracorporeal Photopheresis, medical 128, graft-versus-host disease, white blood cells, infusion, immune system, ECP, apheresis, photodynamic therapy, 8-methoxypsoralen, 8-MOP, ultraviolet A light, UVA, acute cardiac allograft rejection, erythrodermic variants of cutaneous T cell lymphoma, mycosis fungoides, Sézary syndrome, palliative treatment of skin manifestations, cutaneous T-cell lymphoma, lung function, rejection lung transplant

Medical 237 Page 3 of 3